Addressing large, unmet global markets with innovative proprietary products More »
Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »
Identifying early-stage companies with potential to increase value for shareholders More »
OPKO continues to make progress with its program to build a company capable of long-term growth and increasing value to its investors.
Phase 3 Data Supporting Rayaldee(TM) As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings more »
OPKO Investee SciVac Ltd. Enters into Transaction with Levon Resources more »
OPKO Lab Receives Accreditation From College of American Pathologists more »
OPKO Health is an opportunistic research and development company that targets large, high-growth markets.